San Diego-based VivoSim Labs (NASDAQ:VIVS) announced Wednesday that it has received a $5 million milestone payment from Eli Lilly and Company (NYSE:LLY) after the first patient was dosed in a Phase 2 trial of FXR314, an inflammatory bowel disease drug licensed from VivoSim in March 2025. The payment, valued at approximately 1.7 times VivoSim’s closing equity value as of Tuesday, underscores the potential of the partnership but also highlights the stark financial realities facing the micro-cap biotech firm.
The milestone comes as VivoSim projects over 500% revenue growth for fiscal 2027, a target that has drawn scrutiny given the company’s current revenue base of just $131,000 in fiscal 2026—all from royalties. If realized, that growth would push revenue to $786,000, which still represents only about 7.3% of the company’s planned operating expenses for fiscal 2027. The $5 million Lilly payment, while significant, covers roughly half of those projected costs but does not indicate that VivoSim’s core contract research business is self-sustaining.
VivoSim specializes in offering contract research services using its proprietary 3D human liver and intestine models. These so-called new approach methodologies (NAMs) aim to replace animal testing with human-based lab and computer methods before clinical trials. The U.S. Food and Drug Administration has acknowledged the potential of such methods, but adoption remains case-by-case. VivoSim claims its liver model achieves 91% predictive accuracy and its intestine model over 90% sensitivity and accuracy, though these are company-provided figures.
Despite the positive news, the stock closed at $0.8599, up just 3.0% on the day, after opening at $1.49. Trading volume surged to 112.4 million shares—32 times the volume seen on July 10—against a float of only 3.49 million shares. The stock’s decline from its opening price suggests traders remain divided on the company’s long-term prospects. At the close, the implied equity value was about $3.0 million, meaning the Lilly payment alone is 1.66 times that amount.
VivoSim’s annual filing flagged “substantial doubt about our ability to continue as a going concern,” citing tight liquidity. The company burned $10.827 million in cash from operations in fiscal 2026, meaning the $5 million milestone covers about 5.5 months of spending at that rate. Management has indicated it will need additional capital to fund operations. As of March 31, 2026, there were 3.95 million common warrants outstanding with an exercise price of $1.71—above the current share price—and 3.49 million common shares outstanding as of July 10.
Investors are likely to focus on contract research revenue as the true indicator of the company’s health, rather than one-time milestone payments. The $5 million gives VivoSim more runway to market its models, but the 500% growth forecast starts from an extremely low base. The next quarterly filing will reveal whether that growth target is translating into real revenue from paying customers.
